Clinical, Pathologic, and Imaging Features and Biological Markers of Uveal Melanoma

  • Alia B. Rashid
  • Hans E. Grossniklaus
Part of the Methods in Molecular Biology book series (MIMB, volume 1102)


Uveal melanoma has unique clinical and pathologic features including virtually exclusive metastasis to the liver in high-risk cases. In this chapter, the clinical findings in uveal melanoma and diagnostic methods including imaging tests and serum markers are described. Additionally, the histopathologic features including the modified Callender classification and immunohistochemical findings of uveal melanoma are described.

Key words

Uveal melanoma Clinical features Histopathology Biological markers Imaging Prognosis 


  1. 1.
    Damato BE, Coupland SE (2012) Differences in uveal melanomas between men and women from the British Isles. Eye (Lond) 26(2):292–299Google Scholar
  2. 2.
    Shields CL et al (2012) Clinical spectrum and prognosis of uveal melanoma based on Age at presentation in 8,033 cases. Retina 32(7):1363–1372PubMedGoogle Scholar
  3. 3.
    Egan KM et al (1988) Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 32(4):239–251PubMedGoogle Scholar
  4. 4.
    Singh AD, Bergman L, Seregard S (2005) Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 18(1):75–84, viiiPubMedGoogle Scholar
  5. 5.
    Hu DN et al (2005) Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol 140(4):612–617PubMedGoogle Scholar
  6. 6.
    Margo CE, Mulla Z, Billiris K (1998) Incidence of surgically treated uveal melanoma by race and ethnicity. Ophthalmology 105(6):1087–1090PubMedGoogle Scholar
  7. 7.
    Singh AD, Topham A (2003) Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 110(5):956–961PubMedGoogle Scholar
  8. 8.
    Gallagher RP et al (1985) Risk factors for ocular melanoma: Western Canada Melanoma Study. J Natl Cancer Inst 74(4):775–778PubMedGoogle Scholar
  9. 9.
    Seddon JM et al (1990) Host factors, UV radiation, and risk of uveal melanoma. A case-control study. Arch Ophthalmol 108(9):1274–1280PubMedGoogle Scholar
  10. 10.
    van Hees CL et al (1994) Are atypical nevi a risk factor for uveal melanoma? A case-control study. J Invest Dermatol 103(2):202–205PubMedGoogle Scholar
  11. 11.
    Tucker MA et al (1985) Sunlight exposure as risk factor for intraocular malignant melanoma. N Engl J Med 313(13):789–792PubMedGoogle Scholar
  12. 12.
    Singh AD, Turell ME, Topham AK (2011) Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 118(9):1881–1885PubMedGoogle Scholar
  13. 13.
    Bergman L et al (2002) Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci 43(8):2579–2583PubMedGoogle Scholar
  14. 14.
    Burr JM et al (2007) Survival from uveal melanoma in England and Wales 1986 to 2001. Ophthalmic Epidemiol 14(1):3–8PubMedGoogle Scholar
  15. 15.
    Kujala E, Makitie T, Kivela T (2003) Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44(11):4651–4659PubMedGoogle Scholar
  16. 16.
    Seregard S, Kock E (1995) Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmologica Scandinavica 73(4):340–344PubMedGoogle Scholar
  17. 17.
    Kaiserman I, Amer R, Pe’er J (2004) Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 137(2):236–243PubMedGoogle Scholar
  18. 18.
    Bedikian AY (2006) Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 46(1):151–166PubMedGoogle Scholar
  19. 19.
    Kath R et al (1993) Prognosis and treatment of disseminated uveal melanoma. Cancer 72(7):2219–2223PubMedGoogle Scholar
  20. 20.
    Seddon JM et al (1983) A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 101(12):1894–1899PubMedGoogle Scholar
  21. 21.
    Chowers I, Amer R, Pe’er J (2002) The correlation among different immunostaining evaluation methods for the assessment of proliferative activity in uveal melanoma. Curr Eye Res 25(6):369–372PubMedGoogle Scholar
  22. 22.
    McLean IW et al (1983) Modifications of Callender's classification of uveal melanoma at the armed forces institute of pathology. Am J Ophthalmol 96(4):502–509PubMedGoogle Scholar
  23. 23.
    Edge SD, BD Carducci MA, Compton CC. (2009) Chapter 43: Malignant melanoma of the uvea. In: AJCC cancer staging manual. Springer: New York, NYGoogle Scholar
  24. 24.
    Grossniklaus HE, Kivela T, Harbour JW, Finger P (2011) Protocol for the examination of specimens from patients with uveal melanoma. College of American Pathologists Cancer Protocols 2011 [cited 2011 November 2011]; Uveal Melanoma[Available from:
  25. 25.
    Augsburger JJ, Gamel JW (1990) Clinical prognostic factors in patients with posterior uveal malignant melanoma. Cancer 66(7):1596–1600PubMedGoogle Scholar
  26. 26.
    de la Cruz PO Jr, Specht CS, McLean IW (1990) Lymphocytic infiltration in uveal malignant melanoma. Cancer 65(1):112–115PubMedGoogle Scholar
  27. 27.
    Folberg R et al (1992) The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol 23(11):1298–1305PubMedGoogle Scholar
  28. 28.
    Makitie T et al (1999) Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 91(4):359–367PubMedGoogle Scholar
  29. 29.
    Diener-West M et al (2001) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. COMS Report No. 17. Arch Ophthalmol 119(7): 951–965PubMedGoogle Scholar
  30. 30.
    Damato B, Coupland SE (2009) A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. Eye (Lond) 23(12):2152–2160, quiz 2161-2Google Scholar
  31. 31.
    Diener-West M et al (2005) Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 123(12):1639–1643PubMedGoogle Scholar
  32. 32.
    Isager P, Ehlers N, Overgaard J (2004) Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas. Acta Ophthalmol Scand 82(5):517–525PubMedGoogle Scholar
  33. 33.
    McLean IW, Keefe KS, Burnier MN (1997) Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology 104(5):777–780PubMedGoogle Scholar
  34. 34.
    Bellmann C et al (2010) Uveal melanoma: management and outcome of patients with extraocular spread. Br J Ophthalmol 94(5):569–574PubMedGoogle Scholar
  35. 35.
    Coupland SE, Campbell I, Damato B (2008) Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability. Ophthalmology 115(10):1778–1785PubMedGoogle Scholar
  36. 36.
    Diener-West M et al (1992) A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, through 1988. Arch Ophthalmol 110(2):245–250PubMedGoogle Scholar
  37. 37.
    Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the collaborative ocular melanoma study: COMS report no. 21. (2003) Arch Ophthalmol, 121(8): p. 1163–1171Google Scholar
  38. 38.
    Shields CL et al (2009) Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol 127(8):989–998PubMedGoogle Scholar
  39. 39.
    McLean IW et al (1995) Choroidal-ciliary body melanoma. A multivariate survival analysis of tumor location. Ophthalmology 102(7):1060–1064PubMedGoogle Scholar
  40. 40.
    Pach JM et al (1986) Prognostic factors in choroidal and ciliary body melanomas with extrascleral extension. Am J Ophthalmol 101(3):325–331PubMedGoogle Scholar
  41. 41.
    Affeldt JC et al (1980) Prognosis in uveal melanoma with extrascleral extension. Arch Ophthalmol 98(11):1975–1979PubMedGoogle Scholar
  42. 42.
    Font RL, Spaulding AG, Zimmerman LDM (1968) a clinicopathologic report of 54 cases. Transactions—American Academy of Ophthal ology and. Otolaryngology 72(6):877–895Google Scholar
  43. 43.
    Reese AB, Howard GM (1967) Flat uveal melanomas. Am J Ophthalmol 64(6): 1021–1028PubMedGoogle Scholar
  44. 44.
    Reichel E et al (1995) Occult choroidal melanoma presenting as a serous macular detachment. Retina 15(2):167–169PubMedGoogle Scholar
  45. 45.
    Yap EY, Robertson DM, Buettner H (1992) Scleritis as an initial manifestation of choroidal malignant melanoma. Ophthalmology 99(11):1693–1697PubMedGoogle Scholar
  46. 46.
    Shields CL et al (1995) Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology 102(9):1351–1361PubMedGoogle Scholar
  47. 47.
    Shields CL et al (1996) Diffuse choroidal melanoma. Clinical features predictive of metastasis. Arch Ophthalmol 114(8):956–963PubMedGoogle Scholar
  48. 48.
    Shields JA, Shields CL (1999) Atlas of Intraocular Tumors. Lippincott Williams & Wilkins, Philadelphia, PAGoogle Scholar
  49. 49.
    Chaudhry IM, Moster MR, Augsburger JJ (1997) Iris ring melanoma masquerading as pigmentary glaucoma. Arch Ophthalmol 115(11):1480–1481PubMedGoogle Scholar
  50. 50.
    Diekstall F, Demeler U (1988) Therapy-resistant increase in ocular pressure–a rare differential diagnosis: ring melanoma. Fortschr Ophthalmol 85(1):98–100PubMedGoogle Scholar
  51. 51.
    Vasquez LM et al (2008) Ring melanoma of the ciliary body: clinical and ultrasound biomicroscopic characteristics. Can J Ophthalmol 43(2):229–233PubMedGoogle Scholar
  52. 52.
    Demirci H et al (2002) Ring melanoma of the ciliary body: report on twenty-three patients. Retina 22(6):698–706, quiz 852-3PubMedGoogle Scholar
  53. 53.
    Christmas NJ et al (1991) Secondary optic nerve tumors. Surv Ophthalmol 36(3):196–206PubMedGoogle Scholar
  54. 54.
    Lindegaard J, Heegaard S, Prause JU (2002) Histopathologically verified non-vascular optic nerve lesions in Denmark 1940-99. Acta Ophthalmol Scand 80(1):32–37PubMedGoogle Scholar
  55. 55.
    Shammas HF, Blodi FC (1978) Peripapillary choroidal melanomas. Extension along the optic nerve and its sheaths. Arch Ophthalmol 96(3):440–445PubMedGoogle Scholar
  56. 56.
    McLean MJ, Foster WD, Zimmerman LE (1977) Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol 95(1):48–58PubMedGoogle Scholar
  57. 57.
    Damato BE, Paul J, Foulds WS (1996) Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol 80(2):102–108PubMedGoogle Scholar
  58. 58.
    McCurdy J, Gamel J, McLean I (1991) A simple, efficient, and reproducible method for estimating the malignant potential of uveal melanoma from routine H & E slides. Pathol Res Pract 187(8):1025–1027PubMedGoogle Scholar
  59. 59.
    Coleman K et al (1996) Prognostic value of morphometric features and the callender classification in uveal melanomas. Ophthalmology 103(10):1634–1641PubMedGoogle Scholar
  60. 60.
    Pe'er J et al (1994) Mean of the ten largest nucleoli, microcirculation architecture, and prognosis of ciliochoroidal melanomas. Ophthalmology 101(7):1227–1235PubMedGoogle Scholar
  61. 61.
    Seregard S et al (1998) Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma. Ophthalmology 105(3):485–491PubMedGoogle Scholar
  62. 62.
    Gamel JW, McCurdy JB, McLean IW (1992) A comparison of prognostic covariates for uveal melanoma. Invest Ophthalmol Vis Sci 33(6):1919–1922PubMedGoogle Scholar
  63. 63.
    van Diest PJ et al (1992) Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23(6):603–607PubMedGoogle Scholar
  64. 64.
    Angi M et al (2011) Immunohistochemical assessment of mitotic count in uveal melanoma. Acta Ophthalmol 89(2):e155–e160PubMedGoogle Scholar
  65. 65.
    Tapia C et al (2006) Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol 30(1):83–89PubMedGoogle Scholar
  66. 66.
    Folberg R et al (1997) The microcirculation of choroidal and ciliary body melanomas. Eye (Lond) 11(Pt 2):227–238Google Scholar
  67. 67.
    Vernon RB, Sage EH (1995) Between molecules and morphology. Extracellular matrix and creation of vascular form. Am J Pathol 147(4):873–883PubMedGoogle Scholar
  68. 68.
    Ajili F et al (2012) Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34. Ultrastruct Pathol 36(5):336–342PubMedGoogle Scholar
  69. 69.
    Benckert C et al (2012) Impact of microvessel density on lymph node metastasis and survival after curative resection of pancreatic cancer. Surg Today 42(2):169–176PubMedGoogle Scholar
  70. 70.
    Dutta S et al (2012) The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. Br J Cancer 106(4):702–710PubMedGoogle Scholar
  71. 71.
    Iakovlev VV et al (2012) Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. Lab Invest 92(1):46–56PubMedGoogle Scholar
  72. 72.
    Wang J et al (2012) Lymphatic microvessel density as a prognostic factor in non-small cell lung carcinoma: a meta-analysis of the literature. Mol Biol Rep 39(5):5331–5338PubMedGoogle Scholar
  73. 73.
    Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43:175–203PubMedGoogle Scholar
  74. 74.
    Weidner N et al (1991) Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 324(1):1–8PubMedGoogle Scholar
  75. 75.
    Folberg R et al (1993) The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100(9):1389–1398PubMedGoogle Scholar
  76. 76.
    Rummelt V et al (1994) Microcirculation architecture of melanocytic nevi and malignant melanomas of the ciliary body and choroid. A comparative histopathologic and ultrastructural study. Ophthalmology 101(4):718–727PubMedGoogle Scholar
  77. 77.
    Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. (1998) COMS report no. 6. Am J Ophthalmol 125(6):745–766Google Scholar
  78. 78.
    McLean IW, Saraiva VS, Burnier MN (2004) Pathological and prognostic features of uveal melanomas. Can J Ophthalmol 39(4):343–350PubMedGoogle Scholar
  79. 79.
    Shammas HF, Blodi FC (1977) Prognostic factors in choroidal and ciliary body melanomas. Arch Ophthalmol 95(1):63–69PubMedGoogle Scholar
  80. 80.
    Ly LV et al (2010) Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration. Invest Ophthalmol Vis Sci 51(11):5445–5451PubMedGoogle Scholar
  81. 81.
    Durie FH et al (1990) Analysis of lymphocytic infiltration in uveal melanoma. Invest Ophthalmol Vis Sci 31(10):2106–2110PubMedGoogle Scholar
  82. 82.
    Gown AM et al (1986) Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 123(2):195–203PubMedGoogle Scholar
  83. 83.
    Steuhl KP et al (1993) Significance, specificity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors. Ophthalmology 100(2):208–215PubMedGoogle Scholar
  84. 84.
    Ordonez NG, Ji XL, Hickey RC (1988) Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol 90(4):385–390PubMedGoogle Scholar
  85. 85.
    Wick MR, Swanson PE, Rocamora A (1988) Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol 15(4): 201–207PubMedGoogle Scholar
  86. 86.
    Burnier MN Jr, McLean IW, Gamel JW (1991) Immunohistochemical evaluation of uveal melanocytic tumors. Expression of HMB-45, S-100 protein, and neuron-specific enolase. Cancer 68(4):809–814PubMedGoogle Scholar
  87. 87.
    Luyten GP et al (1996) Metastatic uveal melanoma. A morphologic and immunohistochemical analysis. Cancer 78(9):1967–1971PubMedGoogle Scholar
  88. 88.
    Schafer BW, Heizmann CW (1996) The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 21(4):134–140PubMedGoogle Scholar
  89. 89.
    Baudier J, Glasser N, Gerard D (1986) Ions binding to S100 proteins. I. Calcium- and zinc-binding properties of bovine brain S100 alpha alpha, S100a (alpha beta), and S100b (beta beta) protein: Zn2+ regulates Ca2+ binding on S100b protein. J Biol Chem 261(18):8192–8203PubMedGoogle Scholar
  90. 90.
    Cochran AJ et al (1983) Detection of cytoplasmic S-100 protein in primary and metastatic intraocular melanomas. Invest Ophthalmol Vis Sci 24(8):1153–1155PubMedGoogle Scholar
  91. 91.
    Cochran AJ et al (1993) S-100 protein remains a practical marker for melanocytic and other tumours. Melanoma Res 3(5):325–330PubMedGoogle Scholar
  92. 92.
    Gerdes J et al (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133(4):1710–1715PubMedGoogle Scholar
  93. 93.
    Mooy CM et al (1990) Ki-67 immunostaining in uveal melanoma. The effect of pre-enucleation radiotherapy. Ophthalmology 97(10):1275–1280PubMedGoogle Scholar
  94. 94.
    Schilling H, Sehu KW, Lee WR (1997) A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques. Invest Ophthalmol Vis Sci 38(10): 2081–2092PubMedGoogle Scholar
  95. 95.
    Chowers I et al (2001) Comparison of microcirculation patterns and MIB-1 immunoreactivity in iris and posterior uveal melanoma. Ophthalmology 108(2):367–371PubMedGoogle Scholar
  96. 96.
    Al-Jamal RT, Kivela T (2006) KI-67 immunopositivity in choroidal and ciliary body melanoma with respect to nucleolar diameter and other prognostic factors. Curr Eye Res 31(1):57–67PubMedGoogle Scholar
  97. 97.
    Chen YT et al (1996) Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci U S A 93(12):5915–5919PubMedGoogle Scholar
  98. 98.
    Blessing K, Sanders DS, Grant JJ (1998) Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology 32(2):139–146PubMedGoogle Scholar
  99. 99.
    Heegaard S, Jensen OA, Prause JU (2000) Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45. Melanoma Res 10(4):350–354PubMedGoogle Scholar
  100. 100.
    Fernandes BF et al (2007) Immunohistochemical expression of melan-A and tyrosinase in uveal melanoma. J Carcinog 6:6PubMedGoogle Scholar
  101. 101.
    Kivela T, Eskelin S, Kujala E (2006) Metastatic uveal melanoma. Int Ophthalmol Clin 46(1):133–149PubMedGoogle Scholar
  102. 102.
    Zakka KA et al (1980) Malignant melanoma. Analysis of an autopsy population. Ophthalmology 87(6):549–556PubMedGoogle Scholar
  103. 103.
    Gragoudas ES et al (1991) Survival of patients with metastases from uveal melanoma. Ophthalmology 98(3):383–389, discussion 390PubMedGoogle Scholar
  104. 104.
    Diener-West M et al (2004) Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 22(12):2438–2444PubMedGoogle Scholar
  105. 105.
    Donoso LA et al (1985) Metastatic uveal melanoma. Pretherapy serum liver enzyme and liver scan abnormalities. Arch Ophthalmol 103(6):796–798PubMedGoogle Scholar
  106. 106.
    Gombos DS et al (2004) Geographic disparities in diagnostic screening for metastatic uveal melanoma. Ophthalmology 111(12):2254–2258PubMedGoogle Scholar
  107. 107.
    Hicks C, Foss AJ, Hungerford JL (1998) Predictive power of screening tests for metastasis in uveal melanoma. Eye (Lond) 12(Pt 6):945–948Google Scholar
  108. 108.
    Mouriaux F et al (2012) Liver function testing is not helpful for early diagnosis of metastatic uveal melanoma. Ophthalmology 119(8):1590–1595PubMedGoogle Scholar
  109. 109.
    Eskelin S et al (1999) Screening for metastatic malignant melanoma of the uvea revisited. Cancer 85(5):1151–1159PubMedGoogle Scholar
  110. 110.
    Bedikian AY et al (1995) Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 76(9):1665–1670PubMedGoogle Scholar
  111. 111.
    Leyvraz S et al (1997) Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 15(7):2589–2595PubMedGoogle Scholar
  112. 112.
    Mudhar HS et al (2004) A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathology 45(1):1–12PubMedGoogle Scholar
  113. 113.
    Bonfrer JM et al (1998) The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 77(12):2210–2214PubMedGoogle Scholar
  114. 114.
    Bosserhoff AK et al (1999) MIA, a novel serum marker for progression of malignant melanoma. Anticancer Res 19(4A):2691–2693PubMedGoogle Scholar
  115. 115.
    Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90(10):1877–1881PubMedGoogle Scholar
  116. 116.
    Bonfrer JM, Korse CM, Israels SP (1997) Serum S-100 has prognostic significance in malignant melanoma. Anticancer Res 17(4B):2975–2977PubMedGoogle Scholar
  117. 117.
    Hauschild A et al (1999) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56(4):338–344PubMedGoogle Scholar
  118. 118.
    Kadkol SS et al (2006) Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci 47(3):802–806PubMedGoogle Scholar
  119. 119.
    Reiniger IW et al (2005) "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol 243(11):1161–1166PubMedGoogle Scholar
  120. 120.
    Hawkins BS (2004) The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol 138(6):936–951PubMedGoogle Scholar
  121. 121.
    Meziani L et al (2012) Uveal metastasis revealing lung cancer. J Fr Ophtalmol 35(6):420–425PubMedGoogle Scholar
  122. 122.
    Shields CL et al (1997) Survey of 520 eyes with uveal metastases. Ophthalmology 104(8):1265–1276PubMedGoogle Scholar
  123. 123.
    Harada S et al (1983) Solitary pulmonary metastasis of choroidal malignant melanoma: report of an unusual case. Endoscopy 15(6):363–364PubMedGoogle Scholar
  124. 124.
    Tishler M, Greif J, Topilsky M (1986) Solitary pulmonary metastasis of choroidal malignant melanoma simulating primary lung cancer. Eur J Respir Dis 68(3):215–217PubMedGoogle Scholar
  125. 125.
    Frenkel S et al (2009) Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 93(8):1042–1046PubMedGoogle Scholar
  126. 126.
    Sato T et al (1997) Time to systemic metastases in patients with posterior uveal melanoma. Cancer Invest 15(2):98–105PubMedGoogle Scholar
  127. 127.
    Summanen P et al (1993) Survival of patients and metastatic and local recurrent tumor growth in malignant melanoma of the uvea after ruthenium plaque radiotherapy. Ophthalmic Surg 24(2):82–90PubMedGoogle Scholar
  128. 128.
    Feinstein EG et al (2010) Hepatic abnormalities identified on abdominal computed tomography at diagnosis of uveal melanoma. Arch Ophthalmol 128(3):319–323PubMedGoogle Scholar
  129. 129.
    Schoder H, Larson SM, Yeung HW (2004) PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 45(Suppl 1):72S–81SPubMedGoogle Scholar
  130. 130.
    Cohade C et al (2003) Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 44(11):1797–1803PubMedGoogle Scholar
  131. 131.
    Antoch G et al (2003) Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290(24):3199–3206PubMedGoogle Scholar
  132. 132.
    Freudenberg LS et al (2004) Whole-body fluorine-18 fluordeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma. Surv Ophthalmol 49(5):537–540PubMedGoogle Scholar
  133. 133.
    Finger PT et al (2005) Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol 89(10):1270–1274PubMedGoogle Scholar
  134. 134.
    Orcurto V et al (2012) (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study. Melanoma Res 22(1):63–69PubMedGoogle Scholar
  135. 135.
    Servois V et al (2010) Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET). Eur J Surg Oncol 36(2):189–194PubMedGoogle Scholar
  136. 136.
    Wykoff CC et al (2011) Preoperative evaluation for patients with choroidal/ciliary body melanomas: what is necessary? Am J Ophthalmol 151(6):921–924PubMedGoogle Scholar
  137. 137.
    Hendler K et al (2011) Trends in liver function tests: a comparison with serum tumor markers in metastatic uveal melanoma (part 2). Anticancer Res 31(1):351–357PubMedGoogle Scholar
  138. 138.
    Missotten GS et al (2007) S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. Tumour Biol 28(2):63–69PubMedGoogle Scholar
  139. 139.
    Harbour JW (2012) The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res 25(2):171–181PubMedGoogle Scholar
  140. 140.
    Francken AB et al (2006) Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. Eur J Surg Oncol 32(7):780–784PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, New York 2014

Authors and Affiliations

  • Alia B. Rashid
    • 1
  • Hans E. Grossniklaus
    • 2
  1. 1.David G. Cogan Ophthalmic Pathology LaboratoryMassachusetts Eye and Ear Infirmary, Harvard Medical SchoolBostonUSA
  2. 2.Emory University School of MedicineAtlantaUSA

Personalised recommendations